Bank of America just raised its EUR/USD forecast
SAN FRANCISCO—Hans van Houte, the Chief Financial Officer of Nurix Therapeutics, Inc. (NASDAQ:NRIX), recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. The transactions, which took place on March 3, 2025, were conducted under a pre-established Rule 10b5-1 trading plan. The sale comes as the stock has declined nearly 18% year-to-date, according to InvestingPro data, which indicates the company is currently trading below its Fair Value.
Van Houte sold a total of 5,825 shares, generating proceeds of $84,387. The shares were sold at a weighted average price range between $14.3994 and $15.1297 per share. Following these transactions, van Houte holds 33,724 shares in the company. InvestingPro analysis shows the company maintains strong liquidity with a current ratio of 6.46, though six analysts have recently revised their earnings expectations downward.
Nurix Therapeutics, headquartered in San Francisco, is engaged in the development of pharmaceutical preparations. The company continues to focus on advancing its pipeline of drug candidates targeting protein degradation pathways. While the company holds more cash than debt, it reported a significant EBITDA loss of $205 million in the last twelve months. Discover more detailed insights and 8 additional key ProTips with a comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, Nurix Therapeutics reported financial results for the fourth fiscal quarter of 2024, revealing a net loss of $0.75 per share, which was higher than the anticipated $0.64 per share loss. The company’s collaboration and license revenue for the quarter amounted to $13.3 million, falling short of the expected $15.0 million. Research and development expenses reached $67.2 million, surpassing estimates, while selling, general, and administrative expenses were below forecasts. Nurix ended the quarter with approximately $609.6 million in cash, expected to support operations into the first half of 2027.
The U.S. FDA granted Fast Track designation to Nurix’s drug candidate NX-5948 for treating relapsed or refractory Waldenstrom’s macroglobulinemia. This status aims to expedite the development of drugs addressing unmet medical needs. Additionally, Nurix appointed John Northcott as Chief Commercial Officer, bringing extensive commercial experience to the company as it advances NX-5948 into pivotal clinical trials.
Analyst firms have recently adjusted their price targets for Nurix. Stifel raised its target to $36, maintaining a Buy rating, while Needham lowered its target to $28 but also maintained a Buy rating. H.C. Wainwright increased their target to $36, reaffirming a Buy rating, citing a revised valuation based on the company’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.